Mavrilimumab (anti GM-CSF receptor α Mab) efficacious in maintaining disease remission in GCA pts. Phase 2 trial (n=70) 1⃣Disease flare 19% in tx vs. 46% in PBO at 26wk 2⃣Sustained remission 83% vs. 50% in PBO 3⃣Similar AE in both groups @RheumNow #ACR20 Abs#L06 https://t.co/LqiNKJffFo